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The UK Synthetic Biology Research Centre, SYNBIOCHEM, hosted by the Manchester Institute of
Biotechnology at the University of Manchester is delivering innovative technology platforms to facilitate
the predictable engineering of microbial bio-factories for ﬁne and speciality chemicals production. We
provide an overview of our foundry activities that are being applied to grand challenge projects to deliver
innovation in bio-based chemicals production for industrial biotechnology.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).In 2012, the UK Synthetic Biology (SynBio) Roadmap Coordi-
nation Group published the ﬁrst UK SynBio roadmap [1] that set out
a clear strategic vision recognising the enormous contribution that
SynBio, as a key set of underpinning technologies, could make to
industrial biotechnology and thus the UK bio-economy. The rec-
ommendations included sponsoring a network of multidisciplinary
research centres, building a skilled, energised and well-funded UK
SynBio community, investing to responsibly accelerate technology
to market and establishing a SynBio leadership council. The
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ng by Elsevier B.V. on behalf of KeArecommendations to accelerate the commercial translation of
SynBio advances, support industrialisation and commercialisation,
safeguard the capacity of the innovation pipeline, expand the
expert workforce and further develop national and international
partnerships. The total public sector investment in UK SynBio over
the last 8 years has totalled> £300M and is amongst the largest per
capita in the world. Through this timely investment the UK has
established a comprehensive national network comprising Syn-
thetic Biology Research Centres (SBRCs), DNA synthesis facilities,
Centres of Doctoral Training and a national Innovation and
Knowledge Centre to help drive commercial innovation.
Manchester was the global industrial hub at the heart of the
19th-century industrial revolution, when technological advances
transformed the industrial landscape and impacted across all as-
pects of everyday living [3]. At the beginning of a new 21st-century
bio-industrial revolution, it is ﬁtting that once again Manchester is
taking a leading role. Building on a proud tradition in pioneering
the use of biological fermentation processes for chemical produc-
tion (initiated by Chaim Weizmann in Manchester [4]) and as the
historical home of chemical engineering [5], SynBio research in
Manchester is focusing on innovative developments to accelerate
the biological production of diverse high-value chemicals. Throughi Communications Co. This is an open access article under the CC BY-NC-ND license
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(www.synbiochem.co.uk), we have united our expertise from
across the foundational sciences, including biological catalysis,
metabolic engineering, systems biology and computational
modelling to deliver a foundry for metabolic engineering focused
on delivering new SynBio tools/technologies for the production of
ﬁne and speciality chemicals for industrial biotechnology.
Bio-based chemical production processes are already delivering
major economic impact for industrial biotechnology [6], but there is
huge potential for SynBio tools and techniques to dramatically
enrich and expand bio-based production routes to address societal
grand challenges relating to sustainable energy, climate change,
environmental protection and health, providing processes with
reduced toxic by-products, lower fuel consumption, reduced car-
bon footprint and enhanced stability of supply. Early SynBio
breakthroughs have generally focused on the delivery, ﬁne-tuning
and optimised microbial production of individual chemical prod-
ucts, such as the antimalarial precursor artemisinic acid [7] or
various opioids in yeast [8e10 for reviews]. The next generation of
SynBio innovations in Manchester is now directed towards the
engineering of chemical novelty and diversity, targeting metabolic
processes in microorganisms to produce an impressive range of
important chemicals, and high concentrations of industrially
important compounds from antibiotics [11] and vitamins to in-
dustrial ﬂavours, fragrances and pigments [12]. Recent examples
from SYNBIOCHEM programmes, built on the well-established
fundamental research in the Manchester Institute of Biotech-
nology (MIB, www.mib.ac.uk), that have already delivered new
intellectual property, include the development of tools and mi-
crobial factories/hosts relevant to the production of pravastatin
[13], biosynthetic menthol [14] and propane [15]; the development
of new regulatory components (e.g., riboswitches [16]); and the
discovery of new biocatalysts for chemicals production that provide
new routes to alkenes [17,18] and enantiopure amines [19]. These
are supported by unique technology innovations in DNA design and
assembly [20,21] that underpin the rapid construction and evolu-
tion of new parts and pathways through, for example, new ap-
proaches to directed evolution [22,23]. Many of these discoveries
are subject to new SYNBIOCHEM patent submissions, and the work
on bio-propane has supported the formation of an early spinout
company, C3BioTechnologies Ltd.
The University of Manchester's SYNBIOCHEM Centre builds on a
wealth of expertise at the MIB and across campus to provide rapid,
predictable delivery of new microbial platforms for the production
of ﬁne chemicals through a versatile suite of integrated technology
platforms that move us towards a “dial-a-molecule” capability,
which can be focused on a wide range of chemical targets. Co-
directed by Professors Nigel Scrutton, Eriko Takano and Nicholas
Turner, the Centre unites 29 research groups supported by an
expert team of Senior Experimental Ofﬁcers to implement the
Centre's challenge-led collaborative science programmes. A rapidly
expanding SynBio toolbox is enabling our metabolic engineers to
exploit the inherent biosynthetic capacity of microorganisms and
to divert metabolic resources to the production of diverse renew-
able speciality chemicals. We are harnessing new capabilities in the
rational design of new genetic circuits and pathways for the pro-
duction of ﬁne chemicals and the targeted discovery of new
chemical entities with potential bioactive properties which may
provide beneﬁts across a wide range of applications [24].
Amajor focus for the Centre is the fully automated integration of
our tools to create a cyclical DesigneBuildeTest production pipe-
line (Fig. 1) that is ﬂexible, provides access to a wide range of
chemical space, and allows us to deliver projects from the rational
in silico design of parts, circuits and pathways, to their assembly and
testing in engineered microbes, and through iterative cycles oflearning and informed re-design. This unique capability of SYN-
BIOCHEM offers a comprehensive suite of platform technologies for
focused grand challenge projects.
The Centre's Design platform is developing a suite of in silico
tools to support the design of synthetic metabolic pathways [25].
These tools cover enzyme selection, design of reusable genetic
parts (including ribosome binding site and codon optimisation),
intelligent sampling of combinatorial design space through a
Design of Experiments approach, and support of pathway assembly
methods. This work builds on our strong foundation in the devel-
opment of genome mining tools, such as antiSMASH [26], and
automated pipelines for cheminformatics and biosynthetic
pathway prediction, such as RetroPath and related tools [27e30].
The recent development of SensiPath, for the enhanced design of
metabolic pathways with intermediates that are detectable by
biosensors and therefore amenable to high-throughput screening,
further expands this growing arsenal of design tools [31]. Under-
pinning much of these design approaches is expertise in systems
biology and metabolic modelling [32e34], allowing in silico simu-
lations to drive each iteration of the Design-Build-Test-Learn cycle.
Throughout this work, the Centre is committed to the support of
and further development of community standards including SBOL
[35] and SBOL Visual [36].
Based on the resulting design blueprints, the Build platform is
responsible for the manufacturing of catalytic, regulatory and
structural parts; assembly of these parts into pathways, circuits and
microbial scaffolds; and engineering of the chassis for efﬁcient
biosynthesis of target compounds with high product yields. We
have automated our DNA assembly methods including the efﬁcient
construction of directed evolution libraries, that allow the rapid
optimization of the enzyme building blocks of our synthetic path-
ways (SpeedyGenes [20]), and are currently developing more efﬁ-
cient selective library generationmethods. Growth of our collection
of structural, regulatory and bio-catalytic parts is beneﬁting from
automated high-throughput (HTP) preparation and quality control.
We are harnessing our new robotics platforms for automated
combinatorial pathway assembly, chassis growth and target pro-
duction (media dispensing, colony picking, and automated HTP
growth, through to automated metabolite and compound extrac-
tion), to rapidly assemble and screen diverse part libraries and
biochemical pathways, and to phenotypically characterize our
engineered microbial systems. We are developing a regulatory and
biosensor toolkit to facilitate real-time control, sensing and quan-
tiﬁcation of speciﬁc products, intermediates or cofactors from
engineered pathways in living cells, enabling high-throughput
screening and selection. Novel riboswitches are being constructed
from target-speciﬁc aptamers (identiﬁed through our automated
SELEX platform), building on our experience in developing
orthogonal riboswitches as gene regulatory tools [37]. Pathway-
speciﬁc biosensors are also being constructed using sensitive
transcription factor/operator pairs identiﬁed through the mining of
next-generation transcriptome sequencing data. Picodroplet
(SphereFluidics) and fermentation platforms provide the Centre
with capabilities for microbial production and analysis from single
cell level through tomulti-litre scale. Optimisation at the laboratory
scale will inform further collaborative development and evaluation
at larger pilot scales.
Our Test platform, built on a wealth of expertise in targeted
analytics and untargeted metabolomics [38,39], is utilising an in-
tegrated suite of high-throughput screening methods for the
quantiﬁcation of optimised target compound production, assaying
target metabolites and enzymes, as well as tracking pathway in-
termediates and undesired side products or potential metabolic
bottlenecks. Our comprehensive state-of-the-art targeted and
untargeted mass spectrometry platforms are being applied for
Fig. 1. The integrated SYNBIOCHEM pipeline to chemical diversity.
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dedicated ion mobility platform provides additional discriminative
power for compound identiﬁcation. We are signal processing and
deconvolving our data using a range of open source tools, including
our evolving mzMatch toolbox [40], to provide rapid information to
inform the iterative re-design, debugging and optimisation of our
production strains. Our dedicated integrated infrastructure pro-
vides seamless forward and backward data traceability across
analysed experimental data and models. We are using an iterative
active learning strategy for experimental planning to ensure the
generation of high-quality training sets that are used at each iter-
ation to reﬁne and update the models. The Centre is applying
machine-learning workﬂows trained on the analysed data to learn
sequence- and structure-activity relationships [22,28] that feed
back into the Design platform. Similarly, a growing catalogue of
predictive tools that learn from resulting data is applied to the
redesign of additional SynBio components, from chemical diversity
discovery to strain and process optimization [25,41].
Our integrated DesigneBuildeTest platforms are being applied
to a selection of “grand challenge” projects that target key chemical
scaffolds including: Alkaloids, which constitute a vast range of
plant-derived compounds with potent bioactivities and are a
source of numerous drugs and drug precursors [42]; Flavonoids,
traditionally of plant origin with many desirable properties and
used as antibacterial, antitoxin, antiviral and antifungal agents [43];
and Terpenoids, a valuable class of molecules with a range of uses
from ﬂavours and fragrances to antimalarial drugs and biofuel
precursors [44]. SynBio-derived chemical ingredients have alreadyreached the food and cosmetics market, with companies now
focusing on the production of puriﬁed ﬁne chemicals (e.g. noot-
katone fragrance) which once extracted are considered as “natural”
and do not require labelling of the resulting product as containing
genetically modiﬁed organisms. It is, however, early days and the
development of consumer responses to more widespread use of
SynBio ingredients remains to be seen [45]. Pre-market regulation
of SynBio products and speciﬁcally the production processes that
use synthetically modiﬁed organisms (SMO's) will need to be
carefully considered to ensure continued public acceptance. The
recent development of three ofﬁcial Opinion documents by the
Scientiﬁc Committees of the European Commission on potential
risks of SynBio and the associated research needs [46e48] is an
important contribution to this process.
Moreover, complementing our core science programmes, SYN-
BIOCHEM's Responsible Research and Innovation (RRI) platform is
developing major programmes on the societal aspects faced by
SynBio, including real-time assessment and anticipation of
research and innovation trajectories, deliberation and reﬂection on
emerging ethical, regulatory and policy issues, and collaborative
research development. SYNBIOCHEM's RRI platform seeks to
initiate early multiway dialogue, provide expertise, guidance and
training in the responsible governance of SynBio innovation, and
foster public engagement and training for the research community,
in order to anticipate, prepare for and if necessary mitigate the
impacts of SynBio technology in the wider society, economy and
environment [49]. Examples of the Centre's activity in this domain
include contributions to European Commission reports on SynBio
L.F. RA et al. / Synthetic and Systems Biotechnology 1 (2016) 271e275274safety issues [50], involvement in establishing a good practice
framework e The www.Responsibility-Navigator.eu [51], and the
publication of a comprehensive sociological analysis of SynBio as an
emerging scientiﬁc ﬁeld [52].
In summary, SYNBIOCHEM is addressing major SynBio chal-
lenges, employing its foundry concept and integrated technology
platforms to facilitate the predictable engineering of microbial bio-
factories for chemical production. Through its open collaborative
ethos the Centre is proactively engaging with academic and in-
dustrial partners, not only in the UK but also on the international
stage. Development of industrial collaborations, foresight and
awareness is a major focus of the Centre. We are accelerating the
commercial translation of our activities through continued dia-
logue with industrial partners that is enabled through joint co-
funded research projects, that target and apply our technologies
to commercially relevant chemicals at an early stage (e.g. a
collaboration with DSM on a single step fermentative production
route for pravastatin [13]), industry funded PhD studentships and
close partnerships with instrument developers. Building on our
existing productive UK and EU collaborations, the Centre is working
closely with the other UK SBRCs with joint projects, workshops and
events, whilst international partnerships are providing broader
access to technologies and expertise. Examples are UK research
council co-funded partnership awards with China and Japan,
collaboration awards with Brazil and Malaysia, and a steady inﬂux
of international PhD students who join the MIB and the University
of Manchester. Further information about the Centre and routes to
collaboration can be obtained from the SYNBIOCHEM website:
http://synbiochem.co.uk.
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